JP2019519536A5 - - Google Patents

Download PDF

Info

Publication number
JP2019519536A5
JP2019519536A5 JP2018562626A JP2018562626A JP2019519536A5 JP 2019519536 A5 JP2019519536 A5 JP 2019519536A5 JP 2018562626 A JP2018562626 A JP 2018562626A JP 2018562626 A JP2018562626 A JP 2018562626A JP 2019519536 A5 JP2019519536 A5 JP 2019519536A5
Authority
JP
Japan
Prior art keywords
gitr
seq
pharmaceutical composition
sequence
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018562626A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019519536A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/040259 external-priority patent/WO2018005950A1/en
Publication of JP2019519536A publication Critical patent/JP2019519536A/ja
Publication of JP2019519536A5 publication Critical patent/JP2019519536A5/ja
Priority to JP2022000978A priority Critical patent/JP2022058518A/ja
Pending legal-status Critical Current

Links

JP2018562626A 2016-07-01 2017-06-30 Gitrアゴニストおよびcpgを用いた組み合わせ抗腫瘍療法 Pending JP2019519536A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022000978A JP2022058518A (ja) 2016-07-01 2022-01-06 Gitrアゴニストおよびcpgを用いた組み合わせ抗腫瘍療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662357750P 2016-07-01 2016-07-01
US62/357,750 2016-07-01
PCT/US2017/040259 WO2018005950A1 (en) 2016-07-01 2017-06-30 Combined anti tumor therapy with a gitr agonist and cpg

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022000978A Division JP2022058518A (ja) 2016-07-01 2022-01-06 Gitrアゴニストおよびcpgを用いた組み合わせ抗腫瘍療法

Publications (2)

Publication Number Publication Date
JP2019519536A JP2019519536A (ja) 2019-07-11
JP2019519536A5 true JP2019519536A5 (https=) 2020-07-27

Family

ID=59363240

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018562626A Pending JP2019519536A (ja) 2016-07-01 2017-06-30 Gitrアゴニストおよびcpgを用いた組み合わせ抗腫瘍療法
JP2022000978A Pending JP2022058518A (ja) 2016-07-01 2022-01-06 Gitrアゴニストおよびcpgを用いた組み合わせ抗腫瘍療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022000978A Pending JP2022058518A (ja) 2016-07-01 2022-01-06 Gitrアゴニストおよびcpgを用いた組み合わせ抗腫瘍療法

Country Status (5)

Country Link
US (1) US20190263919A1 (https=)
EP (1) EP3478721A1 (https=)
JP (2) JP2019519536A (https=)
CN (1) CN109641967A (https=)
WO (1) WO2018005950A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018000948A (es) * 2015-07-23 2018-09-27 Inhibrx Inc Proteinas de fusion que se unen a gitir multivalentes y multiespecificas.
RU2734432C1 (ru) 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с GITR
CN111732658B (zh) * 2020-06-28 2022-04-26 英诺湖医药(杭州)有限公司 一组gitr单克隆抗体及其医药用途
WO2022036013A1 (en) * 2020-08-11 2022-02-17 Exicure Operating Company Tumor necrosis factor receptor superfamily (tnfrsf) agonists, spherical nucleic acid (sna) tlr9 agonists and checkpoint inhibitors for antitumor therapy

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
CA2348292A1 (en) 1998-10-30 2000-05-11 Takeda Chemical Industries, Ltd. Betacellulin protein-containing preparation
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
DK1638941T3 (da) 2003-05-22 2010-10-11 Abbott Lab Indazol-, benzisoxazol- og benzisothiazolkinaseinhibitorer
CA2586913A1 (en) * 2004-11-09 2006-05-18 University Of Southern California Targeted innate immunity
PT2343320T (pt) 2005-03-25 2018-01-23 Gitr Inc Anticorpos anti-gitr e as suas utilizações
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
US7981415B2 (en) 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
KR101790802B1 (ko) 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 항-gitr 항체
SG181533A1 (en) 2009-12-07 2012-07-30 Univ Leland Stanford Junior Methods for enhancing anti-tumor antibody therapy
KR101566539B1 (ko) 2012-06-08 2015-11-05 국립암센터 신규한 Th2 세포 전환용 에피토프 및 이의 용도
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
SI3148579T1 (sl) 2014-05-28 2021-07-30 Agenus Inc. Proti GITR antitelesa in postopki z njihovo uporabo
PE20170441A1 (es) 2014-06-06 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos
MX2018000948A (es) * 2015-07-23 2018-09-27 Inhibrx Inc Proteinas de fusion que se unen a gitir multivalentes y multiespecificas.
EP3365371B1 (en) 2015-10-22 2025-10-08 Ablynx NV Gitr agonists
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

Similar Documents

Publication Publication Date Title
Yin et al. Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy
Cheng et al. Recent advances in small molecule based cancer immunotherapy
JP2021058197A5 (https=)
Rashidi et al. Treatment of relapsed/refractory acute myeloid leukaemia in adults
Mishan et al. CXCR4 and CCR7: Two eligible targets in targeted cancer therapy
JP2016535009A5 (https=)
JP2019519536A5 (https=)
JP2012196206A5 (https=)
JP6416926B2 (ja) ガン標的化il−12免疫療法
HRP20200383T1 (hr) Ciljana vezna sredstva protiv b7-h1
JP2019508013A5 (https=)
JP2015534578A5 (https=)
RU2021130306A (ru) Композиции il-12, нацеленные на edb
JP2016527286A5 (https=)
JP2015534577A5 (https=)
JP2021521822A5 (https=)
JP2010531140A5 (https=)
JP2012102109A5 (https=)
JP2019203035A5 (https=)
JP2009505676A5 (https=)
Rueda et al. Targeting the chemokine receptor CXCR4 for cancer therapies
JP2017521486A5 (https=)
JP2020517658A5 (https=)
JP2019506862A5 (https=)
JP2019519529A5 (https=)